{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T03:48:18Z","timestamp":1782186498221,"version":"3.54.5"},"reference-count":88,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["akdh.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Kidney Disease and Health"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1053\/j.akdh.2026.04.004","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T02:33:34Z","timestamp":1782182014000},"page":"92-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fabry Disease: Current Perspectives on Diagnosis and Management Strategies"],"prefix":"10.1053","volume":"33","author":[{"given":"Sayna","family":"Norouzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2054-2590","authenticated-orcid":false,"given":"Zohreh Gholizadeh","family":"Ghozloujeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0976-5478","authenticated-orcid":false,"given":"Edgar","family":"Lerma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle R.","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjay","family":"Rastogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1053\/j.akdh.2026.04.004_bib1","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s10897-013-9613-3","article-title":"Fabry disease practice guidelines: recommendations of the National Society of Genetic Counselors","volume":"22","author":"Laney","year":"2013","journal-title":"J Genet Couns"},{"issue":"9","key":"10.1053\/j.akdh.2026.04.004_bib2","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/01.CIR.0000139847.74101.03","article-title":"Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy","volume":"110","author":"Chimenti","year":"2004","journal-title":"Circulation"},{"key":"10.1053\/j.akdh.2026.04.004_bib3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1053\/j.akdh.2026.04.004_bib4","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s12882-025-04127-x","article-title":"Fabry disease in the haemodialysis population: outcome of a UK screening study (SoFAH)","volume":"26","author":"Ng","year":"2025","journal-title":"BMC Nephrol"},{"issue":"1","key":"10.1053\/j.akdh.2026.04.004_bib5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/archneurol.2009.309","article-title":"Inherited metabolic disorders and stroke part 1: fabry disease and mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes","volume":"67","author":"Testai","year":"2010","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1053\/j.akdh.2026.04.004_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2019.129437","article-title":"Progress in the understanding and treatment of Fabry disease","volume":"1864","author":"Miller","year":"2020","journal-title":"Biochim Biophys Acta Gen Subj"},{"issue":"1","key":"10.1053\/j.akdh.2026.04.004_bib7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s13023-024-03131-y","article-title":"A systematic literature review on the health-related quality of life and economic burden of Fabry disease","volume":"19","author":"Jovanovic","year":"2024","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1053\/j.akdh.2026.04.004_bib8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12962-022-00369-w","article-title":"A systematic review of the economic evaluations of Enzyme Replacement Therapy in Lysosomal Storage Diseases","volume":"20","author":"Katsigianni","year":"2022","journal-title":"Cost Eff Resour Alloc"},{"key":"10.1053\/j.akdh.2026.04.004_bib9","article-title":"Cost-effectiveness analysis of enzyme replacement therapy for the treatment of Chinese patients with Fabry disease: a Markov model","volume":"16","author":"Huang","year":"2025","journal-title":"Front Pharmacol"},{"issue":"23","key":"10.1053\/j.akdh.2026.04.004_bib10","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/j.jacc.2016.09.943","article-title":"Later onset Fabry disease, cardiac damage progress in silence: experience with a highly prevalent mutation","volume":"68","author":"Hsu","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.akdh.2026.04.004_bib11","series-title":"Fabry Disease: Perspectives From 5 Years of FOS","article-title":"Fabry disease in females: clinical characteristics and effects of enzyme replacement therapy","author":"Deegan","year":"2006"},{"issue":"6","key":"10.1053\/j.akdh.2026.04.004_bib12","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s40265-021-01486-1","article-title":"Fabry disease: the current treatment landscape","volume":"81","author":"Lenders","year":"2021","journal-title":"Drugs"},{"issue":"Suppl 2","key":"10.1053\/j.akdh.2026.04.004_bib13","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/ndt\/gfab038","article-title":"Precision medicine in Fabry disease","volume":"36","author":"Lenders","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1053\/j.akdh.2026.04.004_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/mgg3.1666","article-title":"The benefits and challenges of family genetic testing in rare genetic diseases\u2014Lessons from Fabry disease","volume":"9","author":"Germain","year":"2021","journal-title":"Mol Genet Genomic Med"},{"issue":"10","key":"10.1053\/j.akdh.2026.04.004_bib15","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.3390\/diagnostics11101779","article-title":"High-risk screening for Fabry disease: a nationwide study in Japan and literature review","volume":"11","author":"Sawada","year":"2021","journal-title":"Diagnostics"},{"key":"10.1053\/j.akdh.2026.04.004_bib16","article-title":"Expert review in diagnostic, therapeutic and follow-up of Fabry disease in Latin America based on patient care standards","volume":"43","author":"Giugliani","year":"2025","journal-title":"Mol Genet Metab Rep"},{"key":"10.1053\/j.akdh.2026.04.004_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1220637","article-title":"Consensus recommendations for the treatment and management of patients with Fabry disease on migalastat: a modified Delphi study","volume":"10","author":"Bichet","year":"2023","journal-title":"Front Med"},{"issue":"1","key":"10.1053\/j.akdh.2026.04.004_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2025.109082","article-title":"Enhancing Fabry disease screening and diagnostic efficiency: integration of enzyme, biomarker, and next-generation sequencing testing","volume":"145","author":"Pan","year":"2025","journal-title":"Mol Genet Metab"},{"issue":"3","key":"10.1053\/j.akdh.2026.04.004_bib19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4103\/ijabmr.ijabmr_161_24","article-title":"Screening for Fabry disease in patients on hemodialysis","volume":"14","author":"Batta","year":"2024","journal-title":"Int J Appl Basic Med Res"},{"issue":"7","key":"10.1053\/j.akdh.2026.04.004_bib20","article-title":"Diagnostic and prognostic perspectives of Fabry disease via fiber evanescent wave spectroscopy advanced by machine learning","volume":"273","author":"Mahlovanyi","year":"2025","journal-title":"Biosens Bioelectron"},{"issue":"6","key":"10.1053\/j.akdh.2026.04.004_bib21","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1002\/ehf2.14091","article-title":"Heart failure in Fabry disease revisited: application of current heart failure guidelines and recommendations","volume":"9","author":"Rob","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1053\/j.akdh.2026.04.004_bib22","article-title":"Algorithm for investigation of fabry disease in cardiomyopathies","volume":"12","author":"Silva SMe","year":"2024","journal-title":"J Inborn Errors Metab Screen"},{"issue":"1","key":"10.1053\/j.akdh.2026.04.004_bib23","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s13023-025-03655-x","article-title":"Applying artificial intelligence to rare diseases: a literature review highlighting lessons from Fabry disease","volume":"20","author":"Germain","year":"2025","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"10.1053\/j.akdh.2026.04.004_bib24","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3390\/diagnostics14020208","article-title":"Anderson\u2013Fabry disease: red flags for early diagnosis of cardiac involvement","volume":"14","author":"Iorio","year":"2024","journal-title":"Diagnostics"},{"issue":"16","key":"10.1053\/j.akdh.2026.04.004_bib25","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1093\/eurheartj\/ehae148","article-title":"Anderson\u2013Fabry disease management: role of the cardiologist","volume":"45","author":"Pieroni","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1053\/j.akdh.2026.04.004_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1420067","article-title":"Inflammation in Fabry disease: stages, molecular pathways, and therapeutic implications","volume":"11","author":"Kurdi","year":"2024","journal-title":"Front Cardiovasc Med"},{"issue":"8","key":"10.1053\/j.akdh.2026.04.004_bib27","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3390\/metabo12080703","article-title":"Metabolic fingerprinting of Fabry disease: diagnostic and prognostic aspects","volume":"12","author":"Rocchetti","year":"2022","journal-title":"Metabolites"},{"issue":"5","key":"10.1053\/j.akdh.2026.04.004_bib28","doi-asserted-by":"crossref","DOI":"10.1111\/eci.14388","article-title":"Imaging predictors of adverse prognosis in Fabry disease cardiomyopathy: a systematic review and meta-analysis","volume":"55","author":"Stankowski","year":"2025","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"10.1053\/j.akdh.2026.04.004_bib29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13023-024-03500-7","article-title":"Clinical management of female patients with Fabry disease based on expert consensus","volume":"20","author":"Brand","year":"2025","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"10.1053\/j.akdh.2026.04.004_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.107585","article-title":"An expert consensus on the recommendations for the use of biomarkers in Fabry disease","volume":"139","author":"Burlina","year":"2023","journal-title":"Mol Genet Metab"},{"issue":"1-2","key":"10.1053\/j.akdh.2026.04.004_bib31","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ymgme.2022.07.010","article-title":"An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease","volume":"137","author":"Germain","year":"2022","journal-title":"Mol Genet Metab"},{"issue":"14","key":"10.1053\/j.akdh.2026.04.004_bib32","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.3390\/jcm10143026","article-title":"Fabry cardiomyopathy: current treatment and future options","volume":"10","author":"Vardarli","year":"2021","journal-title":"J Clin Med"},{"key":"10.1053\/j.akdh.2026.04.004_bib33","doi-asserted-by":"crossref","DOI":"10.1177\/2054358120985627","article-title":"Renal manifestations of Fabry disease: a narrative review","volume":"8","author":"Silva","year":"2021","journal-title":"Can J Kidney Health Dis"},{"issue":"2","key":"10.1053\/j.akdh.2026.04.004_bib34","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s40620-024-02170-9","article-title":"Epidemiology and early predictors of Fabry nephropathy: evaluation of long-term outcomes from a national Fabry centre","volume":"38","author":"Mannan","year":"2025","journal-title":"J Nephrol"},{"issue":"9","key":"10.1053\/j.akdh.2026.04.004_bib35","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","article-title":"Fabry disease: guidelines for the evaluation and management of multi-organ system involvement","volume":"8","author":"Eng","year":"2006","journal-title":"Genet Med"},{"issue":"9","key":"10.1053\/j.akdh.2026.04.004_bib36","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.3390\/genes13091619","article-title":"The benefits of family screening in rare diseases: genetic testing reveals 165 new cases of Fabry disease among at-risk family members of 83 index patients","volume":"13","author":"Moiseev","year":"2022","journal-title":"Genes"},{"issue":"5","key":"10.1053\/j.akdh.2026.04.004_bib37","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3390\/life12050623","article-title":"Fabry\u2019s disease: the utility of a multidisciplinary screening approach","volume":"12","author":"Monte","year":"2022","journal-title":"Life"},{"issue":"2","key":"10.1053\/j.akdh.2026.04.004_bib38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3390\/ijns9020031","article-title":"Newborn screening for fabry disease: current status of knowledge","volume":"9","author":"Gragnaniello","year":"2023","journal-title":"Int J Neonatal Screen"},{"issue":"4","key":"10.1053\/j.akdh.2026.04.004_bib39","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol Genet Metab"},{"issue":"11","key":"10.1053\/j.akdh.2026.04.004_bib40","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet"},{"issue":"1","key":"10.1053\/j.akdh.2026.04.004_bib41","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/ndt\/gfad164","article-title":"Interpretation of GFR slope in untreated and treated adult Fabry patients","volume":"39","author":"Pisani","year":"2024","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"10.1053\/j.akdh.2026.04.004_bib42","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1093\/ndt\/gfad071","article-title":"Cluster analysis of kidney function decline among males with Fabry disease in a large United States electronic health records database","volume":"38","author":"Chiorean","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"10.1053\/j.akdh.2026.04.004_bib43","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.5858\/arpa.2016-0418-RS","article-title":"Fabry nephropathy","volume":"141","author":"Colpart","year":"2017","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"10.1053\/j.akdh.2026.04.004_bib44","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1053\/j.ajkd.2023.03.015","article-title":"Fabry disease nephropathy: histological changes with nonclassical mutations and genetic variants of unknown significance","volume":"82","author":"Santostefano","year":"2023","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.akdh.2026.04.004_bib45","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13023-024-03028-w","article-title":"A review and recommendations for oral chaperone therapy in adult patients with Fabry disease","volume":"19","author":"Nowicki","year":"2024","journal-title":"Orphanet J rare Dis"},{"key":"10.1053\/j.akdh.2026.04.004_bib46","doi-asserted-by":"crossref","unstructured":"M.L. West, L. Geldenhuys and D.G. Bichet, Fabry nephropathy: a treatable cause of chronic kidney disease, Rare Dis Orphan Drugs J. 2024;3(3):22.","DOI":"10.20517\/rdodj.2023.61"},{"issue":"7","key":"10.1053\/j.akdh.2026.04.004_bib47","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/ejhf.1960","article-title":"An expert consensus document on the management of cardiovascular manifestations of Fabry disease","volume":"22","author":"Linhart","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"Suppl 3","key":"10.1053\/j.akdh.2026.04.004_bib48","first-page":"S1","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9","year":"2009","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1053\/j.akdh.2026.04.004_bib49","doi-asserted-by":"crossref","first-page":"2","DOI":"10.20517\/rdodj.2024.45","article-title":"Fabry disease in women: beyond the role of \u201ccarriers\u201d","volume":"4","author":"Barba-Romero","year":"2025","journal-title":"Rare Dis Orphan Drugs J"},{"issue":"11","key":"10.1053\/j.akdh.2026.04.004_bib50","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s40265-016-0607-y","article-title":"Migalastat: first global approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"issue":"14","key":"10.1053\/j.akdh.2026.04.004_bib51","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.3390\/jcm14145131","article-title":"Clinical efficacy and real-world effectiveness of Fabry disease treatments: a systematic literature review","volume":"14","author":"Jovanovic","year":"2025","journal-title":"J Clin Med"},{"issue":"5","key":"10.1053\/j.akdh.2026.04.004_bib52","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40265-019-01090-4","article-title":"Migalastat: a review in Fabry disease","volume":"79","author":"McCafferty","year":"2019","journal-title":"Drugs"},{"issue":"1","key":"10.1053\/j.akdh.2026.04.004_bib53","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1159\/000546152","article-title":"New drugs available for fabry disease","volume":"50","author":"Perretta","year":"2025","journal-title":"Kidney Blood Press Res"},{"issue":"4","key":"10.1053\/j.akdh.2026.04.004_bib54","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s40259-025-00723-3","article-title":"Progress and challenges in the treatment of Fabry disease","volume":"39","author":"Lenders","year":"2025","journal-title":"BioDrugs"},{"issue":"3","key":"10.1053\/j.akdh.2026.04.004_bib55","first-page":"1051","article-title":"A review of current and future treatment strategies for fabry disease: a model for treating lysosomal storage diseases","volume":"3","author":"Alipourfetrati","year":"2015","journal-title":"J Pharmacol Clin Toxicol"},{"issue":"4","key":"10.1053\/j.akdh.2026.04.004_bib56","doi-asserted-by":"crossref","first-page":"340","DOI":"10.20517\/jtgg.2024.41","article-title":"The landscape of current and future therapeutic opportunities for Fabry disease","volume":"8","author":"Giliberti","year":"2024","journal-title":"J Transl Genet Genomics"},{"issue":"23","key":"10.1053\/j.akdh.2026.04.004_bib57","doi-asserted-by":"crossref","first-page":"7195","DOI":"10.3390\/jcm13237195","article-title":"Overcoming resistance in Anderson-Fabry disease: current therapeutic challenges and future perspectives","volume":"13","author":"Carella","year":"2024","journal-title":"J Clin Med"},{"issue":"1","key":"10.1053\/j.akdh.2026.04.004_bib58","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/heartjnl-2023-322712","article-title":"Disease-specific therapy for the treatment of the cardiovascular manifestations of Fabry disease: a systematic review","volume":"110","author":"Orsborne","year":"2023","journal-title":"Heart"},{"issue":"1","key":"10.1053\/j.akdh.2026.04.004_bib59","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM197307052890103","article-title":"Replacement therapy for inherited enzyme deficiency. Use of purified ceramidetrihexosidase in Fabry's disease","volume":"289","author":"Brady","year":"1973","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1053\/j.akdh.2026.04.004_bib60","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/GIM.0b013e3181f13a4a","article-title":"Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry registry","volume":"12","author":"Watt","year":"2010","journal-title":"Genet Med"},{"issue":"2","key":"10.1053\/j.akdh.2026.04.004_bib61","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1053\/j.akdh.2026.04.004_bib62","doi-asserted-by":"crossref","first-page":"440","DOI":"10.2174\/1570159X20666220601124117","article-title":"Fabry disease: current and novel therapeutic strategies. A narrative review","volume":"21","author":"Palaiodimou","year":"2023","journal-title":"Curr Neuropharmacol"},{"issue":"1","key":"10.1053\/j.akdh.2026.04.004_bib63","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3390\/ijms22010206","article-title":"Fabry disease therapy: state-of-the-art and current challenges","volume":"22","author":"Azevedo","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1053\/j.akdh.2026.04.004_bib64","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.akdh.2026.04.004_bib65","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/joim.12647","article-title":"Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease","volume":"282","author":"Lenders","year":"2017","journal-title":"J Intern Med"},{"issue":"10","key":"10.1053\/j.akdh.2026.04.004_bib66","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1007\/s13346-024-01583-0","article-title":"Targeting strategies with lipid vectors for nucleic acid supplementation therapy in Fabry disease: a systematic review","volume":"14","author":"Rodr\u00edguez-Castej\u00f3n","year":"2024","journal-title":"Drug Deliv Transl Res"},{"issue":"1","key":"10.1053\/j.akdh.2026.04.004_bib67","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70073","article-title":"Lentivirus-mediated gene therapy for Fabry disease: 5-year end-of-study results from the Canadian FACTs trial","volume":"15","author":"Khan","year":"2025","journal-title":"Clin Transl Med"},{"key":"10.1053\/j.akdh.2026.04.004_bib68","doi-asserted-by":"crossref","first-page":"1415547","DOI":"10.3389\/fcvm.2024.1415547","article-title":"A systematic literature review to evaluate the cardiac and cerebrovascular outcomes of patients with Fabry disease treated with agalsidase beta","volume":"11","author":"Oudit","year":"2025","journal-title":"Front Cardiovasc Med"},{"issue":"10S","key":"10.1053\/j.akdh.2026.04.004_bib69","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1681\/ASN.20203110S1514d","article-title":"AVR-RD-01, an investigational lentiviral gene therapy for fabry disease, reduces Gb3 substrate in endothelial cells of renal peritubular capillaries: PO1623","volume":"31","author":"Thomas","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.akdh.2026.04.004_bib70","series-title":"Non-Clinical Evaluation of 4D-310 in Combination With Rituximab\/Sirolimus: A Translational Study to Support Adoption of a Novel Prophylactic Immunomodulation Regimen in Clinical Trials in Adults With Fabry Disease","author":"Calton","year":"2025"},{"key":"10.1053\/j.akdh.2026.04.004_bib71","series-title":"Annual WORLDSymposium, San Diego, CA","article-title":"Phase 1\/2 clinical trial evaluating 4D-310 in adults with Fabry disease cardiomyopathy: interim analysis of cardiac and safety outcomes in patients with 12-33 months of follow-up [oral presentation]","author":"Thomas","year":"2024"},{"issue":"3","key":"10.1053\/j.akdh.2026.04.004_bib72","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/biomedicines13030624","article-title":"Fabry disease: insights into pathophysiology and novel therapeutic strategies","volume":"13","author":"Thompson","year":"2025","journal-title":"Biomedicines"},{"issue":"8","key":"10.1053\/j.akdh.2026.04.004_bib73","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.3390\/medicina59081478","article-title":"Treatment of Fabry nephropathy: a literature review","volume":"59","author":"Shimohata","year":"2023","journal-title":"Medicina"},{"issue":"1","key":"10.1053\/j.akdh.2026.04.004_bib74","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13023-025-03646-y","article-title":"Status and frontiers of Fabre disease","volume":"20","author":"Chu","year":"2025","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1053\/j.akdh.2026.04.004_bib75","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5734\/JGM.2023.20.1.6","article-title":"Fabry disease: current treatment and future perspective","volume":"20","author":"Yoo","year":"2023","journal-title":"J Genet Med"},{"key":"10.1053\/j.akdh.2026.04.004_bib76","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s12325-024-03062-x","article-title":"Influence of treatment effect modifiers in fabry disease: a systematic literature review","volume":"42","author":"Azimpour","year":"2024","journal-title":"Adv Ther"},{"issue":"1","key":"10.1053\/j.akdh.2026.04.004_bib77","doi-asserted-by":"crossref","first-page":"4","DOI":"10.20517\/rdodj.2023.50","article-title":"Investigating Fabry disease-some lessons learned","volume":"3","author":"Schiffmann","year":"2024","journal-title":"Rare Dis Orphan Drugs J"},{"issue":"10","key":"10.1053\/j.akdh.2026.04.004_bib78","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1007\/s11255-024-04042-4","article-title":"Fabry disease: a rare disorder calling for personalized medicine","volume":"56","author":"Lerario","year":"2024","journal-title":"Int Urol Nephrol"},{"issue":"2","key":"10.1053\/j.akdh.2026.04.004_bib79","first-page":"231","article-title":"Diagnosis and treatment of Fabry disease. Expert Opinion of the Polish Cardiac Society and the Polish Forum for Fabry Disease","volume":"83","author":"Podolec","year":"2025","journal-title":"Kardiol Pol"},{"issue":"2","key":"10.1053\/j.akdh.2026.04.004_bib80","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2215\/CJN.05570809","article-title":"Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy","volume":"5","author":"Mignani","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"10.1053\/j.akdh.2026.04.004_bib81","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1097\/TP.0000000000002252","article-title":"Long-term outcomes of kidney transplantation in Fabry disease","volume":"102","author":"Ers\u00f6zl\u00fc","year":"2018","journal-title":"Transplantation"},{"issue":"4","key":"10.1053\/j.akdh.2026.04.004_bib82","doi-asserted-by":"crossref","first-page":"645","DOI":"10.5301\/jn.5000214","article-title":"Kidney transplantation and enzyme replacement therapy in patients with Fabry disease","volume":"26","author":"Cybulla","year":"2013","journal-title":"J Nephrol"},{"issue":"3","key":"10.1053\/j.akdh.2026.04.004_bib83","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s40620-023-01853-z","article-title":"Outcomes and management of kidney transplant recipients with Fabry disease: a review","volume":"37","author":"Yu","year":"2024","journal-title":"J Nephrol"},{"issue":"5","key":"10.1053\/j.akdh.2026.04.004_bib84","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ajt.2023.02.020","article-title":"Genetic evaluation of living kidney donor candidates: a review and recommendations for best practices","volume":"23","author":"Thomas","year":"2023","journal-title":"Am J Transplant"},{"issue":"Suppl 8","key":"10.1053\/j.akdh.2026.04.004_bib85","first-page":"S7","article-title":"KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors","volume":"101","year":"2017","journal-title":"Transplantation"},{"issue":"2","key":"10.1053\/j.akdh.2026.04.004_bib86","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2021.12.004","article-title":"Early start of enzyme replacement therapy in pediatric male patients with classical Fabry disease is associated with attenuated disease progression","volume":"135","author":"Van der Veen","year":"2022","journal-title":"Mol Genet Metab"},{"issue":"2","key":"10.1053\/j.akdh.2026.04.004_bib87","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/cge.13546","article-title":"Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients","volume":"96","author":"Germain","year":"2019","journal-title":"Clin Genet"},{"key":"10.1053\/j.akdh.2026.04.004_bib88","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1471-2369-15-72","article-title":"Fabry nephropathy: a review - how can we optimize the management of fabry nephropathy?","volume":"15","author":"Waldek","year":"2014","journal-title":"BMC Nephrol"}],"container-title":["Advances in Kidney Disease and Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949813926000686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949813926000686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T03:05:58Z","timestamp":1782183958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949813926000686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2949813926000686"],"URL":"https:\/\/doi.org\/10.1053\/j.akdh.2026.04.004","relation":{},"ISSN":["2949-8139"],"issn-type":[{"value":"2949-8139","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fabry Disease: Current Perspectives on Diagnosis and Management Strategies","name":"articletitle","label":"Article Title"},{"value":"Advances in Kidney Disease and Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.akdh.2026.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}